Mounjaro®
Starting from £179.99/mo
Start journey Learn moreHair loss during Mounjaro treatment is real, and it worries a lot of people — but the cause is almost never the medicine itself. Most hair shedding reported on tirzepatide is a form of temporary stress-related hair loss triggered by rapid weight change, not a direct drug side effect. Here's what the evidence says, and how to think about it. Mounjaro is a prescription-only medicine; a GPhC-registered prescriber reviews every consultation before any treatment is issued.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
This is a question our prescribers hear most weeks, and it deserves a straight answer. The shedding people notice on Mounjaro is almost always telogen effluvium — a well-recognised pattern in which physiological stress pushes a higher proportion of hair follicles into the resting (telogen) phase at the same time. When those hairs shed two to four months later, the volume can be alarming. The trigger isn't the drug; it's the rapid change in body weight and, sometimes, reduced calorie intake.
This distinction matters. Telogen effluvium is self-limiting. Once the body adapts to its new weight and nutrition stabilises, the hair growth cycle resets and shedding slows. For most people this happens within six to nine months of the peak shed. How tirzepatide affects hair is a separate question from how weight loss does, and understanding the difference changes what you do next.
It is also worth knowing that the Mounjaro SmPC (the prescribing document regulators require manufacturers to maintain) does not list alopecia or hair loss as a common or uncommon adverse reaction. That doesn't make your experience less real; it means the pharmacological mechanism of tirzepatide is not the primary driver. The NHS medicines page for tirzepatide is a useful plain-English reference for the established side-effect profile.
Three things tend to determine whether someone loses noticeable hair during rapid weight loss: the speed of loss, the adequacy of protein intake, and individual genetic baseline.
Speed matters because a steep energy deficit is a stronger physiological stressor than a gradual one. GLP-1 and dual-agonist medicines like tirzepatide are effective precisely because they reduce appetite substantially, but that means some people eat far less than they realise, especially in the early months. Protein is the nutrient most consistently linked to hair health: hair shafts are almost entirely keratin, a protein, and follicle cells are among the fastest-dividing in the body. When overall intake drops sharply, follicles are not a priority tissue. There is also emerging interest in whether deficiencies in iron, zinc and biotin accelerate stress-related shedding, though evidence for supplementation in otherwise well-nourished adults is mixed. How tirzepatide changes your metabolism is worth reading alongside this, because understanding what's happening calorically helps you manage intake more consciously.
Individual genetic baseline is the third factor. People with a personal or family history of androgenetic alopecia (pattern baldness) may find that the telogen shed reveals underlying thinning that was progressing anyway. In those cases, the weight-loss episode accelerates something that was already happening, which is important to know, because it changes the management conversation.
The most practical steps are nutritional. Prioritising adequate protein (aiming for enough to maintain muscle as well as support follicle function) is the single most evidence-consistent action. Specific targets depend on your body weight, activity level and the stage of treatment you're at; those numbers are a conversation for your prescriber or a dietitian, not a one-size rule.
Avoiding crash-level restriction matters too. If nausea on a dose increase has made eating very difficult, and that's been going on for several weeks, flagging it with your clinical team is worth doing, not just for hair but for muscle preservation and general wellbeing. Managing hair shedding while on Mounjaro covers practical strategies in more detail.
Standard hair-care advice also applies: gentle handling of wet hair, avoiding tight styles that add mechanical stress to already fragile shafts, and not combining aggressive heat styling with a period of systemic stress. These are not treatments for telogen effluvium, but they reduce additional breakage on top of the shed.
If shedding is severe, patchy rather than diffuse, accompanied by other symptoms (fatigue, feeling cold, irregular periods), or is not improving after nine or ten months, it is worth asking your GP to check thyroid function and iron stores. Those conditions can both cause hair loss and be aggravated by rapid weight change. Changes to hair texture on tirzepatide (a separate but related question) and the broader picture of hair loss reported on Mounjaro are explored further in our related guides. You can also read about the hair regrowth timeline once shedding slows.
If you're thinking about starting treatment and this is a concern, or you're already treating with Mounjaro and want to raise it, our prescribers are available to talk through the clinical picture. The free consultation is the right place to start, and if you want to understand how weight-loss treatment works more broadly before that, it's a good read. The MHRA's Yellow Card scheme is there if you wish to report any suspected side effect formally.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.